SG11202104448WA - Compositions and methods - Google Patents

Compositions and methods

Info

Publication number
SG11202104448WA
SG11202104448WA SG11202104448WA SG11202104448WA SG11202104448WA SG 11202104448W A SG11202104448W A SG 11202104448WA SG 11202104448W A SG11202104448W A SG 11202104448WA SG 11202104448W A SG11202104448W A SG 11202104448WA SG 11202104448W A SG11202104448W A SG 11202104448WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
Prior art date
Application number
SG11202104448WA
Inventor
Sarah C Gilbert
Sarah Sebastian
Adrian V S Hill
Teresa Lambe
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Publication of SG11202104448WA publication Critical patent/SG11202104448WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C07K14/04—Varicella-zoster virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202104448WA 2018-11-06 2019-11-05 Compositions and methods SG11202104448WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1818084.4A GB201818084D0 (en) 2018-11-06 2018-11-06 Compositions and methods
PCT/GB2019/053131 WO2020095038A1 (en) 2018-11-06 2019-11-05 Compositions and methods

Publications (1)

Publication Number Publication Date
SG11202104448WA true SG11202104448WA (en) 2021-05-28

Family

ID=64655509

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104448WA SG11202104448WA (en) 2018-11-06 2019-11-05 Compositions and methods

Country Status (12)

Country Link
US (1) US20220001007A1 (en)
EP (1) EP3876984A1 (en)
JP (1) JP2022506410A (en)
KR (1) KR20210090208A (en)
CN (1) CN113226364A (en)
AU (1) AU2019374480A1 (en)
CA (1) CA3118641A1 (en)
GB (1) GB201818084D0 (en)
MA (1) MA54143A (en)
MX (1) MX2021005345A (en)
SG (1) SG11202104448WA (en)
WO (1) WO2020095038A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
CN114081943B (en) * 2021-11-08 2024-04-02 中国医学科学院医学生物学研究所 Varicella-zoster mRNA vaccine composition and preparation method and application thereof
CN114163503B (en) * 2021-12-15 2023-11-24 北京交通大学 Two recombinant adenoviruses expressing gE protein of varicella-zoster virus and application thereof
CN114703205A (en) * 2022-03-11 2022-07-05 上海博唯生物科技有限公司 Recombinant protein of herpesvirus glycoprotein gE, vaccine, preparation method and application
WO2023240196A1 (en) * 2022-06-08 2023-12-14 Gritstone Bio, Inc. Compositions and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1950507A (en) * 2004-03-05 2007-04-18 财团法人阪大微生物病研究会 Recombinant varicella-zoster virus
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
US20100330122A1 (en) 2007-07-19 2010-12-30 Gale Smith VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
KR101723605B1 (en) 2014-10-21 2017-04-07 진원생명과학 주식회사 Dna vaccine composition for preventing and treating herpes zoster and method of activating t-cell to vzv antizen by using the same
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
BR112021000965A2 (en) * 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processes and vaccines

Also Published As

Publication number Publication date
CN113226364A (en) 2021-08-06
GB201818084D0 (en) 2018-12-19
KR20210090208A (en) 2021-07-19
JP2022506410A (en) 2022-01-17
EP3876984A1 (en) 2021-09-15
MX2021005345A (en) 2021-09-10
WO2020095038A1 (en) 2020-05-14
AU2019374480A1 (en) 2021-05-27
US20220001007A1 (en) 2022-01-06
CA3118641A1 (en) 2020-05-14
MA54143A (en) 2022-02-16

Similar Documents

Publication Publication Date Title
IL277079A (en) Cartyrin compositions and methods for use
IL280134A (en) Anti-cd112r compositions and methods
IL279897A (en) Fusosome compositions and uses thereof
SG11202011015QA (en) Fusosome compositions and uses thereof
IL268970A (en) Novel compositions and methods
IL268684A (en) Compositions and methods for immunooncology
GB201807325D0 (en) Compositions and methods
GB202201860D0 (en) Novel methods and compositions
IL279755A (en) Senolytic compositions and uses thereof
SG11202104448WA (en) Compositions and methods
GB201815402D0 (en) Compositions and methods and uses relating thereto
GB2578519B (en) Compositions and methods and uses relating thereto
IL274524A (en) Compositions and methods for aquaculturing
GB201817444D0 (en) Methods and compositions
IL277663A (en) Erenumab compositions and uses thereof
ZA202004533B (en) Skin-brightening compositions and methods
GB201807576D0 (en) Compositions and uses thereof
IL290325A (en) Biopharmacuetical compositions and related methods
SG11202108262VA (en) Bacterialcidal methods and compositions
GB201819987D0 (en) Methods and compositions
GB201821138D0 (en) Compositions and uses thereof
GB201812334D0 (en) Compositions and uses thereof
GB201817902D0 (en) Methods and compositions
GB201809880D0 (en) Compositions and methods
GB201804092D0 (en) Methods and compositions